-
EP1841455
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1841455
| EP1841455 - HUMANIZED ANTI-AMYLOID ANTIBODY [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 09.10.2009 Database last updated on 27.07.2024 | Most recent event Tooltip | 09.10.2009 | Application deemed to be withdrawn | published on 11.11.2009 [2009/46] | Applicant(s) | For all designated states Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US | [2007/41] | Inventor(s) | 01 /
SHEN, Wenyan 2757 Autumn Ridge Drive Thousand Oaks, California 91362 / US | 02 /
BIERE-CITRON, Anja, Leona 1272 Wilder Street Thousand Oaks, California 91362 / US | [2007/41] | Representative(s) | Soames, Candida Jane D Young & Co LLP 120 Holborn London EC1N 2DY / GB | [N/P] |
| Former [2007/41] | Soames, Candida Jane D Young & Co 120 Holborn London EC1N 2DY / GB | Application number, filing date | 06719209.6 | 23.01.2006 | [2007/41] | WO2006US02259 | Priority number, date | US20050646658P | 24.01.2005 Original published format: US 646658 P | [2007/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2006081171 | Date: | 03.08.2006 | Language: | EN | [2006/31] | Type: | A1 Application with search report | No.: | EP1841455 | Date: | 10.10.2007 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.08.2006 takes the place of the publication of the European patent application. | [2007/41] | Search report(s) | International search report - published on: | EP | 03.08.2006 | Classification | IPC: | A61K39/395, C07K16/46, A61P25/28 | [2007/41] | CPC: |
C07K16/18 (EP,US);
A61P25/00 (EP);
A61P25/28 (EP);
A01K2267/0312 (EP,US);
A61K2039/505 (EP,US);
C07K2317/24 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/41] | Extension states | AL | Not yet paid | BA | Not yet paid | HR | Not yet paid | MK | Not yet paid | YU | Not yet paid | Title | German: | HUMANISIERTER ANTI-AMYLOID-ANTIKÖRPER | [2007/41] | English: | HUMANIZED ANTI-AMYLOID ANTIBODY | [2007/41] | French: | ANTICORPS ANTI-AMYLOIDE HUMANISE | [2007/41] | Entry into regional phase | 03.04.2007 | National basic fee paid | 03.04.2007 | Designation fee(s) paid | 03.04.2007 | Examination fee paid | Examination procedure | 03.04.2007 | Examination requested [2007/41] | 08.10.2007 | Amendment by applicant (claims and/or description) | 14.12.2007 | Despatch of a communication from the examining division (Time limit: M04) | 14.04.2008 | Reply to a communication from the examining division | 12.12.2008 | Despatch of a communication from the examining division (Time limit: M04) | 24.04.2009 | Application deemed to be withdrawn, date of legal effect [2009/46] | 02.06.2009 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2009/46] | Fees paid | Renewal fee | 03.04.2007 | Renewal fee patent year 03 | 14.01.2009 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO02088307 (LILLY CO ELI [US], et al) [X] 1-38 * pages 2-3; sequence ID NO. 20 *; | [X]US2004043418 (HOLTZMAN DAVID M [US], et al) [X] 1-38 * paragraph [0014]; claims 1-45 *; | [X]WO2004032868 (RINAT NEUROSCIENCE CORP [US], et al) [X] 1-38 * pages 2-10; claims 1-50 *; | [X]EP1431310 (IMMUNO BIOLOGICAL LAB CO LTD [JP], et al) [X] 25,28-30,32-35 * claims 1-42; sequence 17 *; | [X]WO2004065423 (NEMOD BIOTHERAPEUTICS GMBH & C [DE], et al) [X] 25,28-30,32-35 * claims 1-62; sequences 34, 36-47 *; | [XD]US6787637 (SCHENK DALE B [US]) [XD] 1-38 * columns 2-4 *; | [X]WO2004080419 (NEURALAB LTD, et al) [X] 1-38 * page 3; claims 1-158 *; | [X]WO2004110369 (ALEXION PHARMA INC [US]) [X] 25,28-30,32-35 * claims 1-40; sequence 20 *; | [X] - BARD F ET AL, "Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (200008), vol. 6, no. 8, ISSN 1078-8956, pages 916 - 919, XP002154518 [X] 1-38 * the whole document * DOI: http://dx.doi.org/10.1038/78682 | [A] - DAVIES J ET AL, "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, (199609), vol. 2, no. 3, ISSN 1380-2933, pages 169 - 179, XP004070292 [A] 28,29 * abstract * DOI: http://dx.doi.org/10.1016/S1380-2933(96)00045-0 | [A] - HOLT L J ET AL, "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (200311), vol. 21, no. 11, ISSN 0167-7799, pages 484 - 490, XP004467495 [A] 28,29 * abstract * DOI: http://dx.doi.org/10.1016/j.tibtech.2003.08.007 | [A] - SCHENK D ET AL, "Current progress in beta-amyloid immunotherapy", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, (200410), vol. 16, no. 5, ISSN 0952-7915, pages 599 - 606, XP004549620 [A] 1-38 * the whole document * DOI: http://dx.doi.org/10.1016/j.coi.2004.07.012 |